CJC-1295
Growth Hormone Releasing Peptide - GHRH analog studied for sustained GH signalling.
CJC-1295 (without DAC) is a modified growth-hormone-releasing hormone analog, studied for its role in stimulating GH and IGF-1 signalling in endocrine research.
The no-DAC form of CJC-1295 (modified GRF 1-29) is studied for its more pulsatile GH profile, and it is frequently paired with a ghrelin-receptor secretagogue to study the two GH-release mechanisms together. It provides a shorter-acting counterpart to the DAC version.
CJC-1295 specifications
- Sequence
- Modified GHRH(1-29) analog
- Presentation
- Lyophilised powder
- Documented purity
- 99.68% by HPLC
- Available sizes
- 5mg ($45)
- Archived COA lots
- 3
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- GHRH signalling - Studied for potentiation of pulsatile GH and downstream IGF-1 activity.
Reported mechanisms in the literature
- GHRH signalling - A modified GHRH(1-29) analog studied for potentiation of pulsatile GH and downstream IGF-1 signalling in endocrine research. (Teichman et al.)
CJC-1295 frequently asked questions
What is CJC-1295 (no DAC)?
A modified growth-hormone-releasing hormone analog (mod GRF 1-29), studied for stimulating GH and IGF-1 signalling in endocrine research.
Is it approved for human use?
No. It is a research material only, with preclinical data. It is not a medicine or supplement.
How does it differ from the DAC version?
Without the drug-affinity complex it has a shorter half-life, so researchers study it for more pulsatile GHRH signalling.
Documented to 99.68% purity by HPLC · third-party COA every lot · from $45 · For laboratory research use only.
Related Growth Hormone compounds
- Tesamorelin - GHRH analog studied for growth-hormone-axis research.
- Ipamorelin - Selective GH secretagogue studied for receptor-selective GH release.
- CJC-1295 DAC - Long-acting GHRH analog with drug-affinity complex.